U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07529613) titled 'Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma' on April 06.
Brief Summary: To evaluate the safety and tolerability of the combination therapy of T-DXd, nivolumab, and chemotherapy in patients with untreated HER2-low gastric or gastroesophageal junction adenocarcinoma, and to determine the recommended dose. Subsequently, the efficacy and safety at the recommended dose will be assessed.
Study Start Date: Dec. 20, 2023
Study Type: INTERVENTIONAL
Condition:
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Intervention:
DRUG...